# ğŸ“… Daily Report - 2026-02-21

> ä»Šæ—¥ç­›é€‰å‡º **43** æ¡å†…å®¹ï¼Œæ¥è‡ª **2** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
èšç„¦è‚¿ç˜¤å…ç–«æ²»ç–—æ–°ç­–ç•¥ï¼Œå¦‚åŒé¶å‘STING/PI3KÎ³è”åˆç–—æ³•åœ¨èƒ°è…ºç™Œä¸­çš„åº”ç”¨ï¼Œä»¥åŠmiRNAè°ƒæ§è‚¿ç˜¤å¾®ç¯å¢ƒå¯¹è‚ºç™Œå…ç–«æ²»ç–—çš„å½±å“ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒé‡å¡‘ä¸è°ƒæ§**ï¼šç ”ç©¶miR-29a/b1åœ¨è‚ºç™Œä¸­çš„å¤±è°ƒå¦‚ä½•é‡å¡‘è‚¿ç˜¤å¾®ç¯å¢ƒå¹¶å¯¼è‡´å…ç–«æŠ‘åˆ¶ï¼›æ¢ç´¢STING/PI3KÎ³åŒé¶å‘ç­–ç•¥åœ¨å…‹æœèƒ°è…ºç™Œå…ç–«æŠµæŠ—ä¸­çš„ä½œç”¨ã€‚
*   **ç»†èƒå¼‚è´¨æ€§ä¸åŠŸèƒ½æœºåˆ¶è§£æ**ï¼šåˆ©ç”¨å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºè‚ç»†èƒç™Œä¸­ç‰¹å¼‚æ€§Tç»†èƒçš„å¼‚è´¨æ€§ï¼›è§£æSHMT2åœ¨èƒ°è…ºç™Œè¿›å±•ä¸­çš„ä½œç”¨ã€‚
*   **ä¿¡å·é€šè·¯ä¸ç–¾ç—…å…³è”**ï¼šç ”ç©¶CD36/FABP5/PPARÎ´ä¿¡å·è½´åœ¨æ–°ç”ŸæœŸå¿ƒè‚Œç»†èƒå¢æ®–ä¸­çš„ä½œç”¨ï¼›æ¢ç©¶TAK1ä¿¡å·é€šè·¯å¯¹å¿ƒè‚Œæˆçº¤ç»´ç»†èƒè½¬å½•ç»„çš„å½±å“ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **å¤šç»„å­¦æ•´åˆåˆ†æ**ï¼šç»“åˆå•ç»†èƒRNAæµ‹åºï¼ˆscRNA-seqï¼‰ã€å…¨åŸºå› ç»„ç»“åˆ/å ç”¨è°±åˆ†æï¼ˆATAC-seqï¼‰ç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æå¤æ‚ç–¾ç—…ï¼ˆå¦‚é˜¿å°”èŒ¨æµ·é»˜ç—…ï¼‰çš„ç»†èƒå’Œåˆ†å­æœºåˆ¶ã€‚
*   **ç©ºé—´è½¬å½•ç»„å­¦**ï¼šåº”ç”¨äºå¿ƒè‚Œç»†èƒç ”ç©¶ï¼Œæä¾›ç»†èƒå¾®ç¯å¢ƒä¿¡æ¯ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
æ–°å‹å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯scHiCARé¦–æ¬¡å®ç°è½¬å½•ç»„ã€è¡¨è§‚åŸºå› ç»„å’Œ3DåŸºå› ç»„çš„è”åˆåˆ†æï¼›äººä½“é¦–æ¬¡å‘ç°è°ƒæ§ç‚ç—‡çš„å¤©ç„¶â€œå…³é—­å¼€å…³â€ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- å•ç»†èƒå¤šç»„å­¦æŠ€æœ¯å¼€å‘ä¸åº”ç”¨
- ç‚ç—‡è°ƒæ§æœºåˆ¶ç ”ç©¶
- DNAæµ‹åºä¸ç±»è„‘è®¡ç®—æŠ€æœ¯çªç ´
- åŒ–å¦†å“å®‰å…¨æ€§æ£€æµ‹

**æŠ€æœ¯äº®ç‚¹**ï¼š
- scHiCARæ•´åˆRNA-seqã€ATAC-seqåŠHi-CæŠ€æœ¯ï¼Œå®ç°å•ç»†èƒå±‚é¢å¢å¼ºå­-å¯åŠ¨å­äº’ä½œåˆ†æã€‚
- å‘ç°è„‚è‚ªæ¥æºçš„ç¯æ°§äºŒåç¢³ä¸‰çƒ¯é…¸ç±»åˆ†å­ï¼ˆepoxy-oxylipinsï¼‰å¯æŠ‘åˆ¶å…ç–«ç»†èƒæ´»åŒ–ï¼Œè°ƒæ§ç‚ç—‡ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (39æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE285606 miR-29a/b1ç°‡çš„ç¼ºå¤±é‡ç¼–ç¨‹è‚¿ç˜¤å¾®ç¯å¢ƒå¹¶å¯¼è‡´è‚ºç™Œå…ç–«æŠ‘åˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€tumor microenvironmentã€regex:immuno(logy|therapy|suppression)
- ğŸ“ **æè¿°**ï¼šContributors : Jessica Konen ; Yanhua Tian ; Yuanxin XiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune checkpoint inhibitors (ICI), like those that block PD-1/PD-L1, have revolutionized oncological therapy for patients with non-small cell lung cancer (NSCLC). However, most patients demonstrate no clinical benefit or acquire resistance, even in PD-L1+ populations, highlighting the critical need to dissect tumor survival dependencies to overcome resistance. Using our unique Kras/p53-driven lung cancer models which demonstrate acquired or intrinsic resistance to ICI, we performed single cell RNA-sequencing and focused on predicted upstream regulators of differentially expressed genes (DEGs) in the malignant cell cluster of resistant tumors. We found that the micro-RNA, miR-29, was downregulated in tumors with anti-PD-1 resistance, leading to significant upregulation of a multitude of miR-29 targets. Interestingly, we found that the immunosuppressive molecule Enpp2/ATX was one of these genes modulated due to miR-29 loss, and re-expression of miR-29 in anti-PD-1 resistant models diminished ATX tumor expression, diminished the fibrotic microenvironment, and increased CD8 infiltration. Additionally, analysis of lung adenocarcinoma patients revealed miR-29-high patients had increased CD8A expression and enrichment in immunoregulatory pathways. Together, these data provide evidence that the miR-29 family broadly regulates the tumor microenvironment, including anti-tumor immune-related pathways in lung cancer, through control of ATX among many other target genes, with implications in ICI response.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285606)

**2.** â­ **GSE275785 åŒé‡é¶å‘ STING å’Œ PI3KÎ³ å¯æ¶ˆé™¤è°ƒèŠ‚æ€§ B ç»†èƒä»¥å…‹æœèƒ°è…ºç™Œå…ç–«ç–—æ³•çš„ STING è€è¯æ€§ [scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€regex:immuno(logy|therapy|suppression)ã€resistanceã€scRNA
- ğŸ“ **æè¿°**ï¼šContributors : Chengyi Li ; Duxin SunSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe immune suppression in tumors and lymph nodes of pancreatic ductal adenocarcinoma (PDAC), regulated by suppressive myeloid cells and regulatory B (Breg) cells, hinders the effectiveness of immunotherapy. Although STING agonists activate myeloid cells to overcome immune suppression, it expands Breg cells, conferring STING resistance in PDAC. We discovered that blocking PI3KÎ³ during STING activation abolished IRF3 phosphorylation to eliminate Breg cells, while PI3KÎ³ inhibition sustained STING-induced IRF3 phosphorylation to preserve STING function in myeloid cells. Therefore, we developed a dual functional compound SH-273 and its albumin nanoformulation Nano-273, which stimulates STING to activate myeloid cells and inhibits PI3KÎ³ to eliminates Breg cells overcoming STING resistance. Nano-273 achieved systemic antitumor immunity through intravenous administration, which decreases Breg cells and remodels microenvironment in tumors and lymph nodes. Nano-273, combined with anti-PD-1, extended median survival to 200 days in transgenic KPC PDAC mice (KrasG12D-P53R172H-Cre), offering potential for PDAC treatment.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275785)

**3.** â­ **GSE275780 åŒé‡é¶å‘ STING å’Œ PI3KÎ³ å¯æ¶ˆé™¤è°ƒèŠ‚æ€§ B ç»†èƒä»¥å…‹æœèƒ°è…ºç™Œå…ç–«ç–—æ³•çš„ STING è€è¯æ€§ [RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€regex:immuno(logy|therapy|suppression)ã€resistanceã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Chengyi Li ; Duxin SunSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe immune suppression in tumors and lymph nodes of pancreatic ductal adenocarcinoma (PDAC), regulated by suppressive myeloid cells and regulatory B (Breg) cells, hinders the effectiveness of immunotherapy. Although STING agonists activate myeloid cells to overcome immune suppression, it expands Breg cells, conferring STING resistance in PDAC. We discovered that blocking PI3KÎ³ during STING activation abolished IRF3 phosphorylation to eliminate Breg cells, while PI3KÎ³ inhibition sustained STING-induced IRF3 phosphorylation to preserve STING function in myeloid cells. Therefore, we developed a dual functional compound SH-273 and its albumin nanoformulation Nano-273, which stimulates STING to activate myeloid cells and inhibits PI3KÎ³ to eliminates Breg cells overcoming STING resistance. Nano-273 achieved systemic antitumor immunity through intravenous administration, which decreases Breg cells and remodels microenvironment in tumors and lymph nodes. Nano-273, combined with anti-PD-1, extended median survival to 200 days in transgenic KPC PDAC mice (KrasG12D-P53R172H-Cre), offering potential for PDAC treatment.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275780)

**4.** â­ **GSE319709 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºè‚ç»†èƒç™Œä¸­ç—…å› ç‰¹å¼‚æ€§Tç»†èƒå¼‚è´¨æ€§å¹¶æç¤ºå…¶è°ƒæ§æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcarcinomaã€single-cellã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributor : Fengna YanSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHepatocellular carcinoma (HCC) exhibits remarkable etiological heterogeneity, with hepatitis B virus (HBV) infection and metabolic dysfunction-associated steatohepatitis (MASH) emerging as two leading causes. The tumor microenvironment (TME), particularly T cell subsets, plays a pivotal role in tumor progression and immunotherapy response. However, the etiology-specific T cell landscapes in HBV-HCC and MASH-HCC remain poorly characterized.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319709)

**5.** â­ **GSE310857 ç”¨ SHMT2 æ•²ä½æ…¢ç—…æ¯’ï¼ˆäººï¼‰è½¬æŸ“çš„èƒ°è…ºç™Œç»†èƒçš„è½¬å½•ç»„æµ‹åºã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€sequencingã€transcriptome
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe role of SHMT2 in driving pancreatic cancer progression remains incompletely understood. Our previous findings demonstrated that SHMT2 enhances glycolytic metabolism and promotes proliferative and invasive capacities in pancreatic cancer cells. To delineate the precise molecular mechanism underlying these observations, we performed transcriptomic sequencing.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310857)

**6.** â­ **GSE290093 CD36/FABP5/PPARÎ´ä¿¡å·è½´çš„ç©ºé—´è½¬å½•ç»„å­¦å®šä¹‰äº†æ–°ç”Ÿå„¿æœŸè‡ªå‘å¢æ®–çš„å¿ƒè‚Œç»†èƒ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šspatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributors : Abou Bakr M Salama ; Tamer M MohamedSeries Type : OtherOrganism : Mus musculusSpontaneously cycling cardiomyocytes (CMs) represent a rare and unique population in the neonatal heart with the potential to drive cardiac regeneration in adulthood. While previous studies have observed their existence, the mechanisms regulating their cell cycle activity remain poorly understood. Here, we aim to identify the signaling axis that defines the spontaneously proliferating CMs in the neonatal stage.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290093)

**7.** â­ **GSE225630 è½¬ç§»å‰è‚¿ç˜¤å¼•æµæ·‹å·´ç»“çš„è½¬å½•ç»„ï¼Œä¼´æˆ–ä¸ä¼´ TDLN æ”¯é…ä¼¤å®³æ€§ç¥ç»çš„å»ç¥ç»æ”¯é…**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€lymphã€regex:lymph(o|atic)?
- ğŸ“ **æè¿°**ï¼šContributors : Yu Zhang ; Yibo Guo ; Tong JiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe compared the mice tumor-draining lymph nodes(TDLNs) with or without orthotopic tongue xenografts, and with or without denervation of TDLN-innervating nociceptive nerves
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225630)

**8.** **GSE293149 è¡°è€æ§åˆ¶ä¸­ç²¾å­å‘ç”Ÿç‰¹å¼‚æ€§ Argonaute è›‹ç™½å’Œèƒ°å²›ç´ /IGF-1 ä¿¡å·ä¼ å¯¼çš„ç›¸äº’è°ƒæ§ [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šagingã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Thomas Liontis ; Valentina T Pannarale ; Andres R Mansisidor ; Sasiru K Pathiranage ; Jeeya Y Patel ; Alla GrishokSeries Type : Expression profiling by high throughput sequencingOrganism : Caenorhabditis elegansThe potential role of small interfering RNAs (siRNAs) produced from double-stranded RNA in aging has not been fully addressed.The networks of genes regulated by siRNAs and their partner Argonaute proteins are best understood in C. elegans, a pioneeringmodel of aging and small RNA studies. Here, we describe synergistic lifespan extension of insulin/IGF-1 signaling (IIS) mutant age-1(hx546) by rde-4 or alg-3; alg-4 deï¬ciencies. By analyzing gene expression and siRNA populations in these IIS and RNAi mutants,we show here that redundant spermatogenesis-speciï¬c Argonautes ALG-3 and ALG-4 are capable of regulating IIS, potentially through direct control of the Major Sperm Protein (MSP) genes in the germline. MSPs and MSP domains of some mammalian proteins are secreted and directly inhibit the Eph receptor (EphR). In turn, EphR interacts with and destabilizes PTEN, a major negative regulator of IIS. We show that enhanced MSP expression correlates with EphR mislocalization and elevated PTEN levels in oocytes of alg-3/4(-) worms. At the same time, ALG-3/4 expression is regulated by IIS. Thus, we propose mutual regulation of IIS and ALG-3/4 through secreted ligands.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293149)

**9.** **GSE316734 å­å®«å†…è†œç™Œå’Œåµå·¢ç™Œç»†èƒç³»å¯¹DHX9æŠ‘åˆ¶å‰‚çš„æ•æ„Ÿæ€§å’Œè€è¯æœºåˆ¶çš„è¡¨å¾**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€resistance
- ğŸ“ **æè¿°**ï¼šContributor : Huang Tzu-TingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo investigate the DHX9i response across endometrial and ovarian cancer cell lines with diverse backgrounds, total RNA was isolated from three biological replicates of cells treated with or without ATX968 (a DHX9 inhibitor). The RNA samples were then subjected to paired-end RNA sequencing on the NovaSeq X Plus (Illumina) platform.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316734)

**10.** **GSE304899 B ç»†èƒå†…åœ¨ I å‹å¹²æ‰°ç´ ä¿¡å·ä¼ å¯¼å¯¼è‡´ç–«è‹—ç¼ºé™· [VDJ]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼švaccineã€B cell
- ğŸ“ **æè¿°**ï¼šContributors : Xavier LaulhÃ© ; Yasmine Adda-Bouchard ; Guillaume Lopez ; Gabriel Chamberlain ; Anolie Dubreuil ; Tania Charpentier ; Alain LamarreSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAffinity maturation and vaccine efficacy are compromised during chronic viral infections, yet the underlying mechanisms remain unclear. Using the LCMV Cl13 model, we show that IFN-I signaling in B cells plays a central role. IFN-I promotes early B cell activation but reduces clonal diversity and delays IgG1âº B cell entry into germinal centers, impairing high-affinity clone selection. Deletion of IFNAR1 in B cells partially restores NP-specific IGHV1-72 usage and GC access but fails to fully rescue affinity maturation, suggesting a contribution of extrinsic factors. Somatic hypermutation remains elevated in both genotypes, though slightly reduced in IFNAR1â»/â» B cells. BASELINe analysis indicates weaker selection pressure in CDRs, potentially reflecting impaired affinity-based selection. This defect correlates with a reduced TFR/TFH ratio. Our results show that intrinsic and extrinsic IFN-I-dependent mechanisms synergize to disrupt B cell fate. These findings establish IFN-I as a key regulator of humoral immunity and highlight mechanisms underlying poor vaccine response.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304899)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 29 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰

**1.** â­ **scHiCARâ€”â€”è½¬å½•ç»„ã€è¡¨è§‚åŸºå› ç»„å’Œ3DåŸºå› ç»„çš„ä¸‰æ¨¡æ€å•ç»†èƒåˆ†æ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsingle-cellã€genomeã€transcriptomeã€epigenome
- ğŸ“ **æè¿°**ï¼šscHiCAR integrates RNA sequencing, chromatin accessibility, and 3D genome mapping in single cells, enabling high-resolution analysis of enhancer promoter interactions across complex tissues...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/schicar-trimodal-single-cell-profiling-of-transcriptome-epigenome-and-3d-genome/)

**2.** **ç§‘å­¦å®¶å‘ç°äººä½“éšè—çš„ç‚ç—‡â€œå…³é—­å¼€å…³â€ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šinflammation
- ğŸ“ **æè¿°**ï¼šA new human study has uncovered how the body naturally turns off inflammation. Researchers found that fat-derived molecules called epoxy-oxylipins rein in immune cells that can otherwise drive chronic disease. Using a drug to boost these molecules reduced pain faster and lowered harmful inflammatory cells. The discovery could pave the way for safer treatments for arthritis, heart disease, and other inflammation-related conditions.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260219040816.htm)

**3.** **åŸå­çº§é—¨æ§æŠ€æœ¯æœ‰æœ›å½»åº•æ”¹å˜DNAæµ‹åºå’Œç¥ç»å½¢æ€è®¡ç®—ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencing
- ğŸ“ **æè¿°**ï¼šScientists have taken a major step toward mimicking natureâ€™s tiniest gateways by creating ultra-small pores that rival the dimensions of biological ion channelsâ€”just a few atoms wide. The breakthrough opens new possibilities for single-molecule sensing, neuromorphic computing, and studying how matter behaves in spaces barely larger than atoms.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260219040759.htm)

**4.** **ç§‘å­¦å®¶åœ¨æµè¡Œçš„å‡å‘ç‰‡ä¸­å‘ç°è‡´ç™ŒåŒ–å­¦ç‰©è´¨**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šA sweeping new study has uncovered a troubling mix of hazardous chemicals in popular hair extensions, including products made from human hair. Researchers detected dozens of substances linked to cancer, hormone disruption, reproductive harm, and immune system effects in nearly every sample tested. Some products contained flame retardants, organotins, and chemicals associated with increased breast cancer risk, and several exceeded European safety thresholds.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2026/02/260219232620.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| RNA-seq | 9 |
| transcriptome | 8 |
| cancer | 8 |
| sequencing | 5 |
| scRNA | 4 |
| single-cell | 3 |
| resistance | 3 |
| regex:immuno(logy|therapy|suppression) | 3 |
| aging | 2 |
| inflammation | 2 |
| T cell | 2 |
| vaccine | 2 |
| B cell | 2 |
| regex:intestin(e|al) | 2 |
| tumor | 2 |
| transcriptomics | 2 |
| genome | 1 |
| epigenome | 1 |
| metabolic | 1 |
| tumor microenvironment | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (29æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE304898 B ç»†èƒå†…åœ¨ I å‹å¹²æ‰°ç´ ä¿¡å·ä¼ å¯¼å¯¼è‡´ç–«è‹—ç¼ºé™· [GEX]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304898)
- [GSE319605 äººç±»å¿ƒè„ Treg ç»†èƒçš„å•ç»†èƒ RNA æµ‹åº (SORT-seq) (QMU-SF-s001â€“QMU-SF-s012)](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319605)
- [GSE319453 ç³–å°¿ç—…å’Œè„“æ¯’ç—‡å°é¼ è‚ é“è½¬å½•ç»„åˆ†æ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319453)
- [GSE319365 è‚ºæ³¡å·¨å™¬ç»†èƒçš„è®­ç»ƒå…ç–«é€šè¿‡å¢å¼º KLF4-MERTK ä»‹å¯¼çš„èƒåä½œç”¨ä¿ƒè¿›æŸä¼¤æ¶ˆé€€ [ATAC-seq 72h post-LPS]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319365)
- [GSE300520 é¢éƒ¨æµ¸æ¶¦æ€§è„‚è‚ªç˜¤æˆ–å¯¹ç…§ç»„åˆ†ç¦»çš„è„‚è‚ªç»„ç»‡è½¬å½•ç»„æµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300520)
- [GSE294332ï¼šå¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…å°é¼ æ¨¡å‹è¿›è¡Œå¤šç»„å­¦å•æ ¸åˆ†æè¡¨æ˜ï¼ŒACSS2èµ‹äºˆç¥ç»å…ƒæŠµæŠ—tauè›‹ç™½ç—…å˜çš„èƒ½åŠ›ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294332)
- [GSE290127 TAK1ä¿¡å·é€šè·¯å¯¹å¿ƒè„æˆçº¤ç»´ç»†èƒè½¬å½•ç»„çš„å½±å“](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290127)
- [GSE304872 å‰å…°-å·´é›·ç»¼åˆå¾æ—©æœŸå¤–å‘¨ç¥ç»é¶å‘å’Œç–¼ç—›ä¿ƒè¿›è½¬å½•ç»„ç‰¹å¾ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304872)
- [GSE304871 å‰å…°-å·´é›·ç»¼åˆå¾æ—©æœŸå¤–å‘¨ç¥ç»é¶å‘å’Œç–¼ç—›ä¿ƒè¿›è½¬å½•ç»„ç‰¹å¾[æ‰¹é‡RNAæµ‹åº]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304871)
- [GSE303753 é€šè¿‡å¢å¼ºä»£è°¢é€šé‡ä¿ƒè¿›ç”Ÿè‚²é…šç”Ÿç‰©åˆæˆå’Œè´¨ä½“çƒå¢æ®–æ¥å¼ºåŒ–å¶ç‰‡åŒ–å­¦ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303753)
- [GSE293150 è¡°è€æ§åˆ¶ä¸­ç²¾å­å‘ç”Ÿç‰¹å¼‚æ€§ Argonaute è›‹ç™½å’Œèƒ°å²›ç´ /IGF-1 ä¿¡å·ä¼ å¯¼çš„ç›¸äº’è°ƒæ§ [smallRNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293150)
- [GSE270345 çŠ¬ä¹³ç®¡ä¹³å¤´çŠ¶ä¹³è…ºè‚¿ç˜¤è½¬å½•ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270345)
- [GSE316426 MondoAä»‹å¯¼MYCç½‘ç»œä¸èƒ°è…ºå¯¼ç®¡è…ºç™Œæ•´åˆåº”æ¿€ååº”ä¹‹é—´çš„è½¬å½•åè°ƒ[RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316426)
- [GSE307746 æ€¥æ€§å­£èŠ‚æ€§æµæ„Ÿæ„ŸæŸ“æœŸé—´ä¸‹å‘¼å¸é“ä¸­äºº CD8+ T ç»†èƒçš„ååº”](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307746)
- [GSE289318 WNTä»‹å¯¼çš„è‚ ä¸Šçš®è½¬åŒ–è¿‡ç¨‹ä¸­åŸºè´¨Pdgfraè¡¨è¾¾ç»†èƒçš„åŠ¨æ€é‡ç¼–ç¨‹ - å›¾3J](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289318)
- [GSE274811 RNAæµ‹åºï¼šè¿‡è¡¨è¾¾é”šå®šMafG-MITF (T-MGM) çš„WM164ç»†èƒ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274811)
- [GSE295103 å°é¼ è‚¾è„å‡ºç”Ÿåå‘è‚²è¿‡ç¨‹ä¸­çš„å•æ ¸ RNA æµ‹åºã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295103)
- [GSE319738 æ¶å”‘çƒ·é…®ä»‹å¯¼çš„ç¿»è¯‘æŠ‘åˆ¶çš„ä¸Šä¸‹æ–‡ç‰¹å¼‚æ€§å—æŠ—ç”Ÿç´ ç»“æ„è°ƒæ§ [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319738)
- [GSE319710 å•æ ¸ç»†èƒé€šè¿‡è¡€å°æ¿ç›¸äº’ä½œç”¨å’Œæ°§åŒ–åº”æ¿€ä¿¡å·ä¼ å¯¼è€Œæˆä¸º HIV ç›¸å…³åŠ¨è„‰ç²¥æ ·ç¡¬åŒ–çš„åŸºç¡€ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319710)
- [GSE319557 çµé•¿ç±»å²›å¶çš®å±‚ç»†èƒå›¾è°±å’Œæ–°å‹ä¿¡å·å¤„ç†ç­–ç•¥ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319557)
- [GSE319556 å†…çš®ç»†èƒ TLR4 ä¿¡å·ä¼ å¯¼é©±åŠ¨æ–°ç”Ÿå„¿è„‘è†œç‚å°é¼ æ¨¡å‹ä¸­çš„ç»„ç»‡ç‚ç—‡ã€Claudin-5 å†…åŒ–å’Œè¡€ç®¡å±éšœç ´å](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319556)
- [GSE302847 é“æœ¨çš‚è‹·AIIIé€šè¿‡æŠ‘åˆ¶CAR-Trâ€‹â€‹eg IIå¢å¼ºCAR-Tç»†èƒæ•ˆåŠ›å¹¶é¢„é˜²å¤å‘](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302847)
- [GSE290002 CDK8/19æŠ‘åˆ¶å‰‚åœ¨ç»“ç›´è‚ ç™Œä¸­çš„é€‰æ‹©æ€§å’Œæ´»æ€§çš„ç¡®è®¤[ä½“å¤–]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290002)
- [GSE290001 CDK8/19æŠ‘åˆ¶å‰‚åœ¨ç»“ç›´è‚ ç™Œä¸­çš„é€‰æ‹©æ€§å’Œæ´»æ€§çš„ç¡®è®¤[ä½“å†…]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290001)
- [GSE279009 å°é¼ èƒšèƒå¿ƒè„ä¸­PCBP1çš„å¢å¼ºå‹äº¤è”å…ç–«æ²‰æ·€æµ‹åºï¼ˆeCLIP-seqï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279009)
- [GSE279008 èƒšèƒå¿ƒè„è½¬å½•ç»„ï¼Œå¿ƒè‚Œç»†èƒç‰¹å¼‚æ€§ç¼ºä¹ Pcbp1](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279008)
- [GSE279007 æˆå¹´å¿ƒè„ä¸­Aars2ç‰¹å¼‚æ€§å¿ƒè‚Œç»†èƒç¼ºé™·çš„è½¬å½•ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279007)
- [GSE279006 å¿ƒè‚Œç»†èƒç‰¹å¼‚æ€§Aars2ç¼ºé™·çš„èƒšèƒå¿ƒè„è½¬å½•ç»„](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279006)
- [GSE256144 RNA-seq åœ¨ DDX24 æ•²ä½å HUVECs ä¸­çš„åº”ç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256144)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-20 21:46*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*